See the DrugPatentWatch profile for Rystiggo
What is Rystiggo?
Rystiggo (ripasudil hydrochloride hydrate) is a Rho-kinase inhibitor approved for the treatment of progressive vision impairment in patients with certain forms of retinitis pigmentosa [1]. It is administered as eye drops [1].
What other drugs are available for retinitis pigmentosa?
Currently, Rystiggo is the only approved medication specifically for treating progressive vision impairment in retinitis pigmentosa.
How does Rystiggo work?
Rystiggo inhibits Rho-kinase, an enzyme that plays a role in cellular processes. In the context of retinitis pigmentosa, Rho-kinase inhibition is thought to improve retinal function and potentially slow vision loss [1].
When does Rystiggo's patent expire?
Information regarding the specific patent expiration dates for Rystiggo is not publicly available in the provided context. DrugPatentWatch.com may offer detailed patent information for pharmaceutical products [2].
Are there clinical trials for Rystiggo or similar treatments?
Clinical trials have been conducted for Rystiggo to evaluate its efficacy and safety in patients with retinitis pigmentosa [1]. Further research into novel treatments for retinitis pigmentosa is ongoing, exploring various therapeutic approaches to address this group of inherited retinal diseases.
What are the potential side effects of Rystiggo?
The most common side effects reported in clinical trials for Rystiggo include conjunctival hyperemia (redness of the eye), blepharitis (inflammation of the eyelids), eye pain, and hyperkalemia (high potassium levels) [1].
Who makes Rystiggo?
Kowa Company, Ltd. developed and markets Rystiggo [1].